See All Slides - tctmd.com

Slides

Presentation TCT 2012

SDF-1: Circumventing the Application of Cell Products in Heart Failure

Presenter: Warren Sherman

October 22, 2012

Presentation TCT 2012

Perivascular MAPCs: Long Term Follow Up and Next Steps

Presenter: Warren Sherman

October 22, 2012

Presentation TCT 2012

Case Presentation (with Discussion): Complex Multivessel Intervention with FFR and IVUS

Presenter: Bon-Kwon Koo

October 22, 2012

Presentation TCT 2012

Simplifying PCI of Left Main Trifurcation Disease

Presenter: Antonio Colombo

October 22, 2012

Presentation TCT 2012

Frequency, Predictors, and Consequences of Major Vascular Complications After TAVR

Presenter: Philippe Genereux

October 22, 2012

Presentation TCT 2012

STOP-IC: A Prospective, Randomized Trial of Cilostazol after Endovascular Treatment of Femoropopliteal Lesions

Presenter: Hiroyoshi Yokoi

October 22, 2012

Presentation TCT 2012

MicroRNAs: Enhancers or Detractors of Progenitor Cell Function?

Presenter: Stefanie Dimmeler

October 22, 2012

Presentation TCT 2012

Proximal LAD Perforation

Presenter: Subrata Lahiri

October 22, 2012

Presentation TCT 2012

The Importance of Frailty Assessments in TAVR Patient Selection: Phenotype Description, Measurement Tools, and Impact on Clinical Outcomes

Presenter: Philip Green

October 22, 2012

Presentation TCT 2012

Case 3: LAA Occlusion Case

Presenter: Alexander Osiev

October 22, 2012

Advertisement

Slides

SDF-1: Circumventing the Application of Cell Products in Heart Failure

Perivascular MAPCs: Long Term Follow Up and Next Steps

Case Presentation (with Discussion): Complex Multivessel Intervention with FFR and IVUS

Simplifying PCI of Left Main Trifurcation Disease

Frequency, Predictors, and Consequences of Major Vascular Complications After TAVR

STOP-IC: A Prospective, Randomized Trial of Cilostazol after Endovascular Treatment of Femoropopliteal Lesions

MicroRNAs: Enhancers or Detractors of Progenitor Cell Function?

Proximal LAD Perforation

The Importance of Frailty Assessments in TAVR Patient Selection: Phenotype Description, Measurement Tools, and Impact on Clinical Outcomes

Case 3: LAA Occlusion Case

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content